The recognition of TNF-α as a central mediator of several inflammatory processes has led to the investigation of TNF-α inhibitory agents as a therapeutic option for the treatment of inflammatory diseases, especially autoimmune conditions, such as rheumatic diseases and IBD.[32] The US FDA approved infliximab (Remicade®) as the first TNF-α inhibitor drug in October 1998, followed by etanercept (Enbrel®) in November 1998. Here, TNF is linked to inflammatory bowel disease.